Compare LNTH & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNTH | LEGN |
|---|---|---|
| Founded | 1956 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 5.9B |
| IPO Year | 2014 | 2020 |
| Metric | LNTH | LEGN |
|---|---|---|
| Price | $95.42 | $28.16 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 12 |
| Target Price | ★ $87.00 | $61.33 |
| AVG Volume (30 Days) | 765.0K | ★ 2.9M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $343,374,000.00 | N/A |
| Revenue This Year | N/A | $42.68 |
| Revenue Next Year | $14.19 | $30.52 |
| P/E Ratio | $53.29 | ★ N/A |
| Revenue Growth | ★ 3.62 | N/A |
| 52 Week Low | $47.27 | $16.24 |
| 52 Week High | $95.98 | $45.30 |
| Indicator | LNTH | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 75.76 | 65.55 |
| Support Level | $72.35 | $21.27 |
| Resistance Level | N/A | $29.69 |
| Average True Range (ATR) | 2.94 | 2.01 |
| MACD | 0.96 | 0.19 |
| Stochastic Oscillator | 96.97 | 73.78 |
Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue. Its products help healthcare professionals Find, Fight and Follow cancer and diseases and are used by physicians and technologists in clinical settings. The Company produces and markets its products in the United States, mainly to hospitals, independent imaging centers and government facilities, and sells outside the United States through direct and third-party distribution relationships and licensing arrangements in Europe, Canada, Australia, Asia-Pacific, Central America and South America.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.